Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide dual receptor agonist DA-CH5 is superior to exendin-4 in protecting neurons in the 6-hydroxydopamine rat Parkinson model

• Published in: Neural regeneration research Vol. 16; no. 8; pp. 1660 - 1670
• Main Authors: Zhang, Ling-Yu, Jin, Qian-Qian, Hölscher, Christian, Li, Lin
• Format: Journal Article
• Language: English
• Published: India Wolters Kluwer India Pvt. Ltd 01.08.2021; Medknow Publications and Media Pvt. Ltd; Medknow Publications & Media Pvt. Ltd; Gerontology Institute, Shanxi Medical University, Taiyuan, Shanxi Province, China%Department of Forensic Pathology, Shanxi Medical University, Taiyuan, Shanxi Province, China%Department of Neurology, Second Hospital, Shanxi Medical University, Taiyuan, Shanxi Province, China; Research and Experimental Center, Henan University of Chinese Medicine, Zhengzhou, Henan Province, China; Wolters Kluwer - Medknow; Wolters Kluwer Medknow Publications
• Subjects: Agonists; Autophagy; Drug therapy; Evaluation; Glucagon; Glucose; Health aspects; Insulin resistance; Kinases; neurodegenerative disease; parkinson’s disease; insulin resistance; inflammation; glp-1/gip receptor unimolecular co-agonist; Neuroprotective agents; Parkinson's disease; Peptides; Polypeptides; China; neurodegenerative disease; inflammation; insulin resistance; GLP-1/GIP receptor unimolecular co-agonist; Parkinson’s disease; Parkinson's disease
• ISSN: 1673-5374; 1876-7958
• DOI: 10.4103/1673-5374.303045

Patients with Parkinson's disease (PD) have impaired insulin signaling in the brain. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), can re-sensitize insulin signaling. In a recent phase II clinical trial, the first GLP-1 mimic, exendin-4, has shown reliable curative effect in patients with PD. DA-CH5 is a novel GLP-1/GIP receptor unimolecular co-agonist with a novel peptide sequence added to cross the blood-brain barrier. Here we showed that both exendin-4 and DA-CH5 protected against 6-hydroxydopamine (6-OHDA) cytotoxicity, inhibited apoptosis, improved mitogenesis and induced autophagy flux in SH-SY5Y cells via activation of the insulin receptor substrate-1 (IRS-1)/alpha serine/threonine-protein kinase (Akt)/cAMP response element-binding protein (CREB) pathway. We also found that DA-CH5 (10 nmol/kg) daily intraperitoneal administration for 30 days post-lesion alleviated motor dysfunction in rats and prevented stereotactic unilateral administration of 6-OHDA induced dopaminergic neurons loss in the substantia nigra pars compacta. However, DA-CH5 showed curative effects in reducing the levels of α-synuclein and the levels of pro-inflammatory cytokines (tumor necrosis factor-α, interleukin-1β). It was also more effective than exendin-4 in inhibiting apoptotic process and protecting mitochondrial functions. In addition, insulin resistance was largely alleviated and the expression of autophagy-related proteins was up-regulated in PD model rats after DA-CH5 treatment. These results in this study indicate DA-CH5 plays a therapeutic role in the 6-OHDA-unilaterally lesioned PD rat model and is superior to GLP-1 analogue exendin-4. The study was approved by the Animal Ethics Committee of Shanxi Medical University of China.